<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>METHITEST- methyltestosterone tablet </strong><br>Global Pharmaceuticals, Division of Impax Laboratories Inc.<br></p></div>
<h1>METHITEST™ <br>(Methyltestosterone) <br>Tablets, USP <br>CIII</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">METHITEST™ Tablets contain methyltestosterone, USP, a synthetic androgen. <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> are steroids that develop and maintain primary and secondary male sex characteristics. Methyltestosterone Tablets are to be taken orally.</p>
<p><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> are derivatives of cyclopentanoperhydrophenanthrena. Endogenous <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are C-19 steroids with a side chain at C-17, and with two angular methyl groups. Testosterone is the primary endogenous androgen. In their active form, all drugs in the class have a 17-beta-hydroxy group. 17-alpha alkylation (methyltestosterone) increases the pharmacologic activity per unit weight compared to testosterone when given orally.</p>
<p>Methyltestosterone is the 17α-methyl derivative of testosterone, the true testicular hormone. Chemically, methyltestosterone is 17β-hydroxy-17-methylandrost-4-en-3-one, with the empirical formula C<span class="Sub">20</span>H<span class="Sub">30</span>O<span class="Sub">2</span>, a molecular weight of 302.5, and the following structural formula:</p>
<table class="Noautorules" width="100%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr><td align="center"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=77bb4ef4-c10e-4acc-8225-651d003f4561&amp;name=methitest-01.jpg"></td></tr>
<tr><td align="center">C<span class="Sub">20</span>H<span class="Sub">30</span>O<span class="Sub">2 </span>m.w. 302.46 (CAS-58-18-4)<br>17β-Hydroxy-17-methylandrost-4-en-3-one</td></tr>
</tbody>
</table>
<p>Methyltestosterone is a white to creamy-white, odorless, slightly hydroscopic powder. It is practically insoluble in water, and is soluble in alcohol and other organic solvents. Methyltestosterone Tablets contain methyltestosterone, USP and acacia, lactose monohydrate, confectioner's sugar, corn starch, powdered cellulose, sodium lauryl sulfate, magnesium stearate, pregelatinized starch, and guar gum.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="clinical"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Endogenous <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of prostate, seminal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span>, penis and scrotum; the development of male hair distribution, such as beard, pubic, chest, and axillary hair; laryngeal enlargement, vocal cord thickening; alterations in body musculature and fat distribution. Drugs in this class also cause retention of nitrogen, sodium, potassium, phosphorus, and decreased urinary excretion of calcium. <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> have been reported to increase protein anabolism and decrease protein catabolism. Nitrogen balance is improved only when there is sufficient intake of calories and protein.</p>
<p><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> are responsible for the growth spurt of adolescence and for the eventual termination of linear growth which is brought about by fusion of the epiphyseal growth centers. In children, exogenous <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> accelerate linear growth rates, but may cause a disproportionate advancement in bone maturation. Use over long periods may result in fusion of the epiphyseal growth centers and termination of growth process. <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> have been reported to stimulate the production of red blood cells by enhancing the production of erythropoietic stimulating factor.</p>
<p>During exogenous administration of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>, endogenous testosterone release is inhibited through feedback inhibition of pituitary luteinizing hormone (LH). With large doses of exogenous <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>, spermatogenesis may also be suppressed through feedback inhibition of pituitary follicle stimulating hormone (FSH). There is a lack of substantial evidence that <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are effective in <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>, surgery, convalescence, and functional <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span>.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="section-2.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Testosterone given orally is metabolized by the gut and 44% is cleared by the liver in the first pass. Oral doses as high as 400 mg per day are needed to achieve clinically effective blood levels for full replacement therapy. The synthetic androgen (methyltestosterone) is less extensively metabolized by the liver and has a longer half-life. It is more suitable than testosterone for oral administration.</p>
<p>Testosterone in plasma is 98% bound to a specific testosterone-estradiol binding globulin, and about 1% is free. Generally, the amount of this sex-hormone binding globulin in the plasma will determine the distribution of testosterone between free and bound forms, and the free testosterone concentration will determine its half-life.</p>
<p>About 90% of a dose of testosterone is excreted in the urine as glucuronic and sulfuric acid conjugates of testosterone and its metabolites; about 6% of a dose is excreted in the feces, mostly in the unconjugated form. Inactivation of testosterone occurs primarily in the liver. Testosterone is metabolized to various 17-keto steroids through two different pathways. As reported in the literature, the half-life of testosterone varies considerably, ranging from 10 to 100 minutes.</p>
<p>In many tissues the activity of testosterone appears to depend on reduction to dihydrotestosterone, which binds to cytosol receptor proteins. The steroid-receptor complex is transported to the nucleus where it initiates transcription events and cellular changes related to androgen action.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="IAU"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<dl>
<dt class="Bold">1.</dt>
<dd>
<span class="Bold">Males</span><p class="First"><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone:</p>
<ul class="Disc">
<li>
<span class="Italics">Primary <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span> (congenital or acquired)</span> — Testicular failure due to <span class="product-label-link" type="condition" conceptid="437655" conceptname="Undescended testicle">cryptorchidism</span>, bilateral torsion, <span class="product-label-link" type="condition" conceptid="4171915" conceptname="Orchitis">orchitis</span>, vanishing testis syndrome, or orchidectomy.</li>
<li>
<span class="Italics">Hypogonadotropic <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span> (congenital or acquired)</span> — Gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. 				<p class="First">Safety and efficacy of methyltestosterone in men with "age-related <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span>" (also referred to as "late-onset <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span>" have not been established.</p>
</li>
<li><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> may be used to stimulate puberty in carefully selected males with clearly <span class="product-label-link" type="condition" conceptid="440366" conceptname="Delay in sexual development AND/OR puberty">delayed puberty</span>. These patients usually have a familial pattern of <span class="product-label-link" type="condition" conceptid="440366" conceptname="Delay in sexual development AND/OR puberty">delayed puberty</span> that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see <a href="#warnings">WARNINGS</a>).</li>
</ul>
</dd>
<dt class="Bold">2.</dt>
<dd>
<span class="Bold">Females</span><p class="First"><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field.</p>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="contrain"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Methyltestosterone Tablets are contraindicated in men with carcinomas of the breast or with known or suspected carcinomas of the prostate, and in women who are or may become pregnant. When administered to pregnant women, <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> cause <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> of the external genitalia of the female fetus. This <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> includes clitoromegaly, abnormal vaginal development, and fusion of genital folds to form a scrotal-like structure. The degree of <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">masculinization</span> is related to the amount of drug given and age of the fetus, and is most likely to occur in the female fetus when the drugs are given in the first trimester. If the patient becomes pregnant while taking these drugs, she should be apprised of the potential hazard to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warnings"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">In patients with breast cancer, androgen therapy may cause <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> by stimulating <span class="product-label-link" type="condition" conceptid="78308" conceptname="Osteolysis">osteolysis</span>. In this case, the drug should be discontinued.</p>
<p>Prolonged use of high doses of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> has been associated with the development of <span class="product-label-link" type="condition" conceptid="4240725" conceptname="Peliosis hepatis">peliosis hepatis</span> and <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">hepatic neoplasms</span> including hepatocellular carcinoma. (See <a href="#pre_CMIF">PRECAUTIONS: CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY</a>.) <span class="product-label-link" type="condition" conceptid="4240725" conceptname="Peliosis hepatis">Peliosis hepatis</span> can be a life-threatening or fatal complication.</p>
<p><span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">Cholestatic hepatitis</span> and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> occur with 17-alpha-alkylandrogens (such as methyltestosterone) at a relatively low dose. If <span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">cholestatic hepatitis</span> with <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> appears or if liver function tests become abnormal, the androgen should be discontinued and the etiology should be determined. Drug-induced <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> is reversible when the medication is discontinued.</p>
<p>Geriatric patients treated with <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> may be at an increased risk of developing <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> and prostatic carcinoma although conclusive evidence to support this concept is lacking.</p>
<p>There have been postmarketing reports of venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>, including <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), in patients using testosterone products, such as methyltestosterone. Evaluate patients who report symptoms of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, warmth and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> in the lower extremity for DVT and those who present with acute <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> for PE. If a venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic event</span> is suspected, discontinue treatment with methyltestosterone and initiate appropriate workup and management.</p>
<p>Long term clinical safety trials have not been conducted to assess the cardiovascular outcomes of testosterone replacement therapy in men. To date, epidemiologic studies and randomized controlled trials have been inconclusive for determining the risk of major adverse cardiovascular events (MACE), such as non-fatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, with the use of testosterone compared to non-use. Some studies, but not all, have reported an increased risk of MACE in association with use of testosterone replacement therapy in men. Patients should be informed of this possible risk when deciding whether to use or to continue to use methyltestosterone.</p>
<p><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> with or without <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> may be a serious complication in patients with pre-existing cardiac, renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>. In addition to discontinuation of the drug, diuretic therapy may be required.</p>
<p><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span> frequently develops and occasionally persists in patients being treated for <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span>.</p>
<p>Androgen therapy should be used cautiously in healthy males with <span class="product-label-link" type="condition" conceptid="440366" conceptname="Delay in sexual development AND/OR puberty">delayed puberty</span>. The effect on bone maturation should be monitored by assessing bone age of the wrist and hand every 6 months. In children, androgen treatment may accelerate bone maturation without producing compensatory gain in linear growth. This adverse effect may result in compromised adult stature. The younger the child the greater the risk of compromising final mature height.</p>
<p>This drug has not been shown to be safe and effective for the enhancement of athletic performance. Because of the potential risk of serious adverse health effects, this drug should not be used for such purpose.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">Woman should be observed for signs of <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> (deepening of the voice, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, clitoromegaly, and menstrual irregularities). Discontinuation of drug therapy at the time of evidence of mild <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilism</span> is necessary to prevent irreversible <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span>. Such <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> is usual following androgen use at high doses. The patient and physician may decide that some <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> will be tolerated during treatment for breast carcinoma.</p>
<p><span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span> or excessive sexual stimulation may develop. Males, especially the elderly, may become overstimulated. In treating males for symptoms of <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">climacteric</span>, avoid stimulation to the point of increasing the nervous, mental, and physical activities beyond the patient's cardiovascular capacity.</p>
<p><span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">Oligospermia</span> and reduced ejaculatory volume may occur after prolonged administration or excessive dosage.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-6.2"></a><p></p>
<h2>Information for the Patients</h2>
<p class="First">The physician should instruct patients to report any of the following side effects of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>:</p>
<p><span class="Bold">Adult or Adolescent Males: </span>Too frequent or persistent erections of the penis.</p>
<p><span class="Bold">Women: </span><span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">Hoarseness</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, changes in menstrual periods, or more hair on the face.</p>
<p><span class="Bold">All Patients: </span>Any <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, changes in skin color, or <span class="product-label-link" type="condition" conceptid="4144411" conceptname="Swollen ankle">ankle swelling</span>.</p>
<p>Any male adolescent patient receiving <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> for <span class="product-label-link" type="condition" conceptid="440366" conceptname="Delay in sexual development AND/OR puberty">delayed puberty</span> should have bone development checked every 6 months.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-6.3"></a><p></p>
<h2>Laboratory Tests</h2>
<ol class="Arabic">
<li>Women with disseminated breast carcinoma should have frequent determination of urine and serum calcium levels during the course of androgen therapy (See <a href="#warnings">WARNINGS</a>).</li>
<li>Because of the hepatotoxicity associated with the use of 17-alpha-alkylated <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>, liver function tests should be obtained periodically.</li>
<li>Periodic (every 6 months) X-ray examinations of bone age should be made during treatment of prepubertal males to determine the rate of bone maturation and the effects of androgen therapy on the epiphyseal centers.</li>
<li>Hemoglobin and hemotocrit should be checked periodically for <span class="product-label-link" type="condition" conceptid="435790" conceptname="Secondary polycythemia">polycythemia</span> in patients who are receiving high doses of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-6.4"></a><p></p>
<h2>Drug Interactions</h2>
<ol class="Arabic">
<li>
<span class="Bold">Anticoagulants: </span>C-17 substituted derivatives of testosterone, such as methandrostenolone have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. Patients receiving anticoagulant therapy require close monitoring, especially when <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are started or stopped.</li>
<li>
<span class="Bold">Oxyphenbutazone: </span>Concurrent administration of oxyphenbutazone and <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> may result in elevated serum levels of oxyphenbutazone.</li>
<li>
<span class="Bold">Insulin: </span>In diabetic patients, metabolic effects of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> may decrease blood glucose and insulin requirements.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-6.5"></a><p></p>
<h2>Drug/Laboratory Test Interference</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> may decrease levels of thyroxine-binding globulin, resulting in decreased total T4 serum levels and increased resin uptake of T3 and T4. Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="pre_CMIF"></a><a name="section-6.6"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.6.1"></a><p></p>
<h3>Animal Data</h3>
<p class="First">Testosterone has been tested by subcutaneous injection and implantation in mice and rats. The implant induced cervical-uterine tumors in mice, which metastasized in some cases. There is suggestive evidence that injection of testosterone into some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of female mice increases their susceptibility to <span class="product-label-link" type="condition" conceptid="4101758" conceptname="Hepatocellular carcinoma">hepatoma</span>. Testosterone is also known to increase the number of tumors and decrease the degree of differentiation of chemically induced carcinomas of the liver in rats.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.6.2"></a><p></p>
<h3>Human Data</h3>
<p class="First">There are rare reports of hepatocellular carcinoma in patients receiving long-term therapy with <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> in high doses. Withdrawal of the drugs did not lead to regression of the tumors in all cases.</p>
<p>Geriatric patients treated with <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> may be at an increased risk of developing <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> and prostatic carcinoma although conclusive evidence to support this concept is lacking.</p>
<p>This compound has not been tested for mutagenic potential. However, as noted above, carcinogenic effects have been attributed to treatment with adrogenic hormones. The potential carcinogenic effects likely occur through a hormonal mechanism rather than by a direct chemical interaction mechanism.</p>
<p>Impairment of fertility was not tested directly in animal species. However, as noted below under ADVERSE REACTIONS, <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">oligospermia</span> in males and <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> in females are potential adverse effects of treatment with Methyltestosterone Tablets. Therefore, impairment of fertility is a possible outcome of treatment with Methyltestosterone Tablets.</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-6.7"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-6.7.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.7.1.1"></a><p></p>
<h4>Pregnancy Category X</h4>
<p class="First">(See <a href="#contrain">CONTRAINDICATIONS</a>).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-6.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-6.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Androgen therapy should be used very cautiously in children and only by specialists who are aware of the adverse effects on bone maturation. Skeletal maturation must be monitored every six months by an X-ray of the hand and wrist (See <a href="#IAU">INDICATIONS &amp; USAGE</a>, and <a href="#warnings">WARNINGS</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2>Endocrine and Urogenital</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.1"></a><p></p>
<h3>Female</h3>
<p class="First">The most common side effects of androgen therapy are <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> and other menstrual irregularities, inhibition of gonadotropin secretion, and <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span>, including deepening of the voice and clitoral enlargement. The latter usually is not reversible after <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> are discontinued. When administered to a pregnant woman, <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> cause <span class="product-label-link" type="condition" conceptid="4035817" conceptname="Virilization">virilization</span> of external genitalia of the female fetus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.2"></a><p></p>
<h3>Male</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span>, and excessive frequency and duration of penile erections. <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">Oligospermia</span> may occur at high dosage (see <a href="#clinical">CLINICAL PHARMACOLOGY</a>).</p>
<p><span class="Bold Italics">Skin and Appendages: </span><span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">Hirsutism</span>, male pattern of <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">baldness</span>, and <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span>: </span> <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></p>
<p><span class="Bold Italics">Fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Disturbances</span>: </span>Retention of sodium, chloride, water, potassium, calcium, and <span class="product-label-link" type="condition" conceptid="4106483" conceptname="P">inorganic phosphates</span>.</p>
<p><span class="Bold Italics">Gastrointestinal: </span><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, alterations in liver function tests, rarely hepatocellular neoplasma and <span class="product-label-link" type="condition" conceptid="4240725" conceptname="Peliosis hepatis">peliosis hepatis</span> (see <a href="#warnings">WARNINGS</a>).</p>
<p><span class="Bold Italics">Hematologic: </span>Suppression of clotting factors II, V, VII, and X, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients on concomitant anticoagulant therapy, and <span class="product-label-link" type="condition" conceptid="435790" conceptname="Secondary polycythemia">polycythemia</span>.</p>
<p><span class="Bold Italics">Nervous System: </span>Increased or decreased libido, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and generalized <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>.</p>
<p><span class="Bold Italics">Metabolic: </span>Increased serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous thromboembolism</span>.</p>
<p><span class="Bold Italics">Miscellaneous: </span>Rarely, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<p class="First"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact IMPAX Laboratories, Inc. at 1-800-934-6729 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-8"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>Controlled Substance Class</h2>
<p class="First">METHYLTESTOSTERONE Tablets are classified as controlled substances under the Anabolic Steroids Control Act of 1990 and have been assigned to Schedule III.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> of medication may be reflected in the occurrence of the signs and symptoms associated with testosterone-anabolic drugs. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and appearance of the early manifestations of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> should be looked for. However, there has been no report of acute overdosage with <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Prior to initiating methyltestosterone, confirm the diagnosis of <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span> by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate days and that these serum testosterone concentrations are below the normal range.</p>
<p>Dosage must be strictly individualized. The suggested dosage for <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> varies depending on the age, sex, and diagnosis of the individual patient. Adjustments and duration of dosage will depend upon the patient's response and the appearance of adverse reactions.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>Males</h2>
<p class="First">In the androgen-deficient male the guideline for replacement therapy indicates the usual initial dosage of 10-50 mg daily.</p>
<p>Various dosage regimens have been used to induce pubertal changes in hypogonadel males: some experts have advocated lower dosages initially, gradually increasing the dose as puberty progresses, with or without a decrease to maintenance levels. Other experts emphasize that higher dosages are needed to induce pubertal changes and lower dosages can be used for maintenance after puberty. The chronological and skeletal ages must be taken into consideration, both in determining the initial dose and in adjusting the dose.</p>
<p>Dosages used in <span class="product-label-link" type="condition" conceptid="440366" conceptname="Delay in sexual development AND/OR puberty">delayed puberty</span> generally are in the lower ranges of those given above, and are for limited duration, for example, 4 to 6 months.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Females</h2>
<p class="First">Women with metastatic breast carcinoma must be followed closely because androgen therapy occasionally appears to accelerate the disease. Thus, many experts prefer to use the shorter acting androgen preparations rather than those with prolonged activity for treating breast carcinoma particularly during the early stages of androgen therapy.</p>
<p>Guideline dosages of <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> for use in the palliative treatment of women with metastatic breast cancer are 50-200 mg daily.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Each compressed, single-scored, round, white tablet contains 10 mg of methyltestosterone for oral use. Each tablet is debossed with "7037" on one side, and scored on the other side.</p>
<table class="Noautorules" width="75%">
<col align="left" valign="top" width="50%">
<col align="right" valign="top" width="50%">
<tbody class="Headless"><tr>
<td align="left">Bottles of 100 tablets</td>
<td align="right">NDC 0115-7037-01</td>
</tr></tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<p class="First"><span class="Bold">Protect from Light, Moisture and Heat. </span>Store at controlled room temperature, 15°-30°C (59°-86°F).</p>
<p>This package is not for household dispensing. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure, as required.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<p class="First"><span class="Bold">Rx Only</span></p>
<p>Mfg. by:<br>IMPAX Laboratories, Inc.<br>Hayward, California 94544 USA</p>
<p>Dist. by:<br>Global Pharmaceuticals<br>Division of IMPAX Laboratories, Inc.<br>Philadelphia, PA 19124 USA</p>
<p>120-09<br>Rev. 04/2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 10 mg Bottle Label</h1>
<p class="First"><span class="Bold">GLOBAL<span class="Sup">®</span></span></p>
<p>NDC 0115-7037-01</p>
<p><span class="Bold">CIII <br>METHITEST™ <br>MethylTESTOSTERone <br>Tablets, USP</span></p>
<p><span class="Bold">10 mg</span></p>
<p>Rx only</p>
<p><span class="Bold">100 TABLETS</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=77bb4ef4-c10e-4acc-8225-651d003f4561&amp;name=methitest-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>METHITEST 		
					</strong><br><span class="contentTableReg">methyltestosterone tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0115-7037</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METHYLTESTOSTERONE</strong> (METHYLTESTOSTERONE) </td>
<td class="formItem">METHYLTESTOSTERONE</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ACACIA</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POWDERED CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GUAR GUM</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">7037</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0115-7037-01</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA080767</td>
<td class="formItem">10/17/1974</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Global Pharmaceuticals, Division of Impax Laboratories Inc.
							(116732830)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>045f0b76-eab7-4d79-8283-a6b4fd8a066a</div>
<div>Set id: 77bb4ef4-c10e-4acc-8225-651d003f4561</div>
<div>Version: 6</div>
<div>Effective Time: 20150427</div>
</div>
</div> <div class="DistributorName">Global Pharmaceuticals, Division of Impax Laboratories Inc.</div></p>
</body></html>
